AzTrials
AzTrials

Urinary Tract InfectionNCT07204769

Microbiological Characterization and Antibiotic Resistance Profiling of Providencia Spp,: An Emerging Pathogen Isolated From Urinary Tract Infections

An observational study of Urinary Tract Infection, run by Assiut University at 1 site in Egypt.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Aims of the Research: 1. Isolation and identification of Providencia spp. from UTIs. 2. Genotypic confirmation of Providencia isolates. 3. Determination of antimicrobial sensitivity patterns of isolated Providencia spp. 4. Characterization of some virulence factors of Providencia spp. 5. Read more about this study

Who is it for?
Any age
Conditions the study is for
Urinary Tract Infection
What is being tested?
Antibiotic sensitivity
How many people
241 participants
Where
1 siteEgypt
Study dates
1 May 2026to Sep 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients with UTI diagnosed through clinical examination and urine analysis.

Who may be able to join

  • Patients with UTI diagnosed through clinical examination and urine analysis. Informed consent will be obtained from each patient before Participation in the study.

Who cannot join

  • Patients currently on antibiotics.
  • Patients with any anatomical abnormalities in the urinary tract C) Patients having UTI by gram +ve organisms.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Aya Tareq Diab, Bachelor's degree contact

+201157456012

ay39090ta@gmail.com

Rawhia Fathy Abdel-Hamid, Doctorate contact

01110965594

rawhiafathy@aun.edu.eg

Egypt1 site

  • Assiut University

    Asyut

Other trials in Egypt

About this study

Official title: Microbiological Characterization and Antibiotic Resistance Profiling of Providencia Spp,: An Emerging Pathogen Isolated From Urinary Tract Infections.

Aims of the Research:

  1. Isolation and identification of Providencia spp. from UTIs.
  2. Genotypic confirmation of Providencia isolates.
  3. Determination of antimicrobial sensitivity patterns of isolated Providencia spp.
  4. Characterization of some virulence factors of Providencia spp.
  5. Molecular characterization of multidrug-resistance gene antibiotics.
  6. Determination of risk factors for Providencia UTIs.
Read the detailed description

Urinary tract infections (UTIs) are among the most common bacterial infections worldwide, with Escherichia coli, Klebsiella spp., Proteus spp., and Pseudomonas spp. representing the majority of isolated pathogens in both community and hospital settings. Providencia spp., although historically considered uncommon, are increasingly recognized as opportunistic pathogens.

International surveillance studies report that Providencia accounts for ~1-2% of urinary isolates, with higher prevalence (up to 6-12%) in catheter-associated infection.

The Providencia genus, nestled within the Enterobacterales order as part of Proteus and Morganella relatives, consists of Gram-negative bacteria that are adept at producing urease .

The genus includes 14 distinct species, with Providencia rettgeri, Providencia stuartii, Providencia alcalifaciens, and Providencia hangzhouensis standing out due to their pronounced relevance to human infections. Renowned for their association with urinary tract infections, these pathogens also possess the capability to inflict a broader spectrum of severe ailments, such as ocular diseases,peritonitis, neonatal septicemia or bloodstream infections and meningitis.

Providencia stuartii is able to adhere to and invade HeLa-M epithelial cell line.

They form biofilms and have several virulence genes . Providencia spp. may be susceptible to third- and fourth-generation cephalosporins, aztreonam, imipenem, and meropenem. Providencia species have variable susceptibilities to fluoroquinolones, aminoglycosides, and trimethoprim- sulfamethoxazole (TMP-SMX). Generally, Providencia spp. are frequently resistant to tetracyclines, penicillins, and first- and second- generation cephalosporins .

Providencia spp.are intrinsically resistant to polymyxins and tigecycline, which are considered last- resort antibiotics for other resistant pathogens .

In Egypt, several studies have investigated the prevalence of UTI pathogens, consistently reporting E. coli, Klebsiella spp., and Proteus spp. as the most frequent isolates .

However, no published Egyptian data specifically describe the prevalence, antimicrobial resistance patterns, or clinical significance of Providencia spp. in UTIs.

This gap highlights the need for focused research on Providencia in the Egyptian context. Studying its frequency, antibiotic resistance mechanisms, and clinical relevance would not only provide novel insights but also contribute to improving diagnosis, empirical therapy, and infection control strategies in Egyptian hospitals .

Being tested
Antibiotic sensitivity
Medical subject headings
Urinary Tract Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Antibiotic sensitivityDrug

    Molecular characterization of multidrug-resistance gene antibiotics.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Determination of prevalence of Providencia species refers specifically to urinary tract infection patients with gram-negative bacterial isolates.

    Measured: Through study completion, an average of 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Oct 2025
  2. Study start1 May 2026 (estimated)
  3. Primary completion1 Aug 2027 (estimated)
  4. Study completionSep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
241 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07204769
Sponsor's protocol ID
Providencia UTI
Status last verified
Sep 2025
First submitted
22 Sep 2025
Last updated
2 Oct 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Çetin ET, et al. Providencia spp. in nosocomial urinary infections. Turk J Med Sci. 1998;28(1):59-62

  • Ewing WH. The tribe Proteeae: its nomenclature and taxonomy. Int J Syst Evol Microbiol. 1962;12(3):93-102

  • Charbek EPN. Providencia infections treatment & management: medical care, surgical care, consultations. Medscape. 2019

  • Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006 Aug;26(8):1099-110. doi: 10.1592/phco.26.8.1099.

    PubMed 16863487

  • Guidone GHM, Cardozo JG, Silva LC, Sanches MS, Galhardi LCF, Kobayashi RKT, Vespero EC, Rocha SPD. Epidemiology and characterization of Providencia stuartii isolated from hospitalized patients in southern Brazil: a possible emerging pathogen. Access Microbiol. 2023 Oct 18;5(10):000652.v4. doi: 10.1099/acmi.0.000652.v4. eCollection 2023.

    PubMed 37970084

  • Kurmasheva N, Vorobiev V, Sharipova M, Efremova T, Mardanova A. The Potential Virulence Factors of Providencia stuartii: Motility, Adherence, and Invasion. Biomed Res Int. 2018 Feb 21;2018:3589135. doi: 10.1155/2018/3589135. eCollection 2018.

    PubMed 29682537

  • Dong X, Xiang Y, Yang P, Wang S, Yan W, Yuan Y, Zhou S, Zhou K, Liu J, Zhang Y. Novel Providencia xianensis sp. nov.: A multidrug-resistant species identified in clinical infections. Eur J Clin Microbiol Infect Dis. 2024 Jul;43(7):1461-1467. doi: 10.1007/s10096-024-04821-y. Epub 2024 May 7.

    PubMed 38714595

  • O'Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev. 2000 Oct;13(4):534-46. doi: 10.1128/CMR.13.4.534.

    PubMed 11023955

  • Wie SH. Clinical significance of Providencia bacteremia or bacteriuria. Korean J Intern Med. 2015 Mar;30(2):167-9. doi: 10.3904/kjim.2015.30.2.167. Epub 2015 Feb 27. No abstract available.

    PubMed 25750557

Questions about this trial

What is this clinical trial studying?

An observational study of Urinary Tract Infection, run by Assiut University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 2 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Aya Tareq Diab, Bachelor's degree (+201157456012, ay39090ta@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Determination of prevalence of Providencia species refers specifically to urinary tract infection patients with gram-negative bacterial isolates. (time frame: Through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07204769, which also lists 9 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in